EMA Withdrawn: Varuby (rolapitant) — TESARO Bio Netherlands B.V.

View source ↗

Summary

EMA has withdrawn Varuby (rolapitant) from the market in the Netherlands/EMA record; the withdrawal concerns vomiting, nausea, and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Nausea
• Vomiting

Drugs mentioned

• Varuby (rolapitant)

Snippet

Status: Withdrawn. Therapeutic area: Vomiting;Nausea;Cancer. MAH: TESARO Bio Netherlands B.V.. Decision date: 11/03/2019